IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical development company...
FDA's Office of Nonprescription Products Will Now Handle Marketing Approval Process for Anti-Allergy Drug PreHistin(TM) IRVINE, Calif., Jan. 19...
Thomas Stankovich, Former Vice President and Chief Financial Officer of MP Biomedicals, Ribapharm and ICN / Valeant Pharmaceuticals Joins Cobalis...
European Patent Office Allows New Patent for PreHistin(TM) -- 'Cyanocobalamin Treatment in Allergic Disease' IRVINE, Calif., Nov. 2...
Safe, Non-Drowsy PreHistin(TM) Achieves Clinical and Statistical Significance (p= 0.0028) Versus Placebo; Study Demonstrates Dramatic Reduction in...
IRVINE, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical biotech company...
Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms in Humans IRVINE...
Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange IRVINE, Calif., Oct...
Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange IRVINE, Calif., Aug. 27...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads